IL314576A - Treatment methods using T-type calcium channel modulators - Google Patents

Treatment methods using T-type calcium channel modulators

Info

Publication number
IL314576A
IL314576A IL314576A IL31457624A IL314576A IL 314576 A IL314576 A IL 314576A IL 314576 A IL314576 A IL 314576A IL 31457624 A IL31457624 A IL 31457624A IL 314576 A IL314576 A IL 314576A
Authority
IL
Israel
Prior art keywords
treatment
methods
calcium channel
type calcium
channel modulators
Prior art date
Application number
IL314576A
Other languages
English (en)
Hebrew (he)
Original Assignee
Praxis Prec Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Prec Medicines Inc filed Critical Praxis Prec Medicines Inc
Publication of IL314576A publication Critical patent/IL314576A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL314576A 2022-02-03 2023-02-03 Treatment methods using T-type calcium channel modulators IL314576A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263306340P 2022-02-03 2022-02-03
PCT/US2023/061973 WO2023150703A2 (en) 2022-02-03 2023-02-03 Methods of treatment using t-type calcium channel modulators

Publications (1)

Publication Number Publication Date
IL314576A true IL314576A (en) 2024-09-01

Family

ID=87552982

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314576A IL314576A (en) 2022-02-03 2023-02-03 Treatment methods using T-type calcium channel modulators

Country Status (10)

Country Link
US (1) US20250170114A1 (https=)
EP (1) EP4472633A4 (https=)
JP (1) JP2025505578A (https=)
KR (1) KR20240144291A (https=)
CN (1) CN118785905A (https=)
AU (1) AU2023216271A1 (https=)
CA (1) CA3243616A1 (https=)
IL (1) IL314576A (https=)
MX (1) MX2024009559A (https=)
WO (1) WO2023150703A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025188619A1 (en) * 2024-03-04 2025-09-12 Praxis Precision Medicines, Inc. Methods of treating parkinson's disease with t-type calcium channel modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009500340A (ja) * 2005-06-29 2009-01-08 メルク エンド カムパニー インコーポレーテッド 4−フルオロ−ピペリジンt型カルシウムチャネルアンタゴニスト
EP3340988B1 (en) * 2015-11-12 2025-04-09 Afasci, Inc. Ion channel inhibitory compounds, pharmaceutical formulations and uses
US11744825B2 (en) * 2018-08-28 2023-09-05 Afasci, Inc. Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds
EP3996746A4 (en) * 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF
IL297642A (en) * 2020-04-29 2022-12-01 Praxis Prec Medicines Inc Methods for using t-type calcium channel modulators
US20240025852A1 (en) * 2020-11-09 2024-01-25 Praxis Precision Medicines, Inc. T-type calcium channel modulators and methods of use thereof
US20250295646A1 (en) * 2022-05-09 2025-09-25 Praxis Precision Medicines, Inc. Methods of use of t-type calcium channel modulators

Also Published As

Publication number Publication date
EP4472633A2 (en) 2024-12-11
US20250170114A1 (en) 2025-05-29
CA3243616A1 (en) 2023-08-10
EP4472633A4 (en) 2026-01-14
WO2023150703A2 (en) 2023-08-10
AU2023216271A1 (en) 2024-08-15
JP2025505578A (ja) 2025-02-28
CN118785905A (zh) 2024-10-15
MX2024009559A (es) 2024-09-23
WO2023150703A3 (en) 2023-09-14
KR20240144291A (ko) 2024-10-02

Similar Documents

Publication Publication Date Title
IL289722A (en) Formulations of t-type calcium channel modulators and methods of use thereof
EP4142764A4 (en) Methods of use of t-type calcium channel modulators
IL315503A (en) Treatment methods
IL320711A (en) Treatment methods
IL314581A (en) Treatment methods using P-TAU181 LEVEL
IL314576A (en) Treatment methods using T-type calcium channel modulators
EP4522271A4 (en) METHODS FOR USING T-TYPE CALCIUM CHANNEL MODULATORS
GB202201824D0 (en) Methods of treatment
HK40117383A (en) Methods of treatment using t-type calcium channel modulators
IL325983A (en) TRPM3 modulators for pain treatment
HK40089115A (en) Methods of use of t-type calcium channel modulators
GB202201819D0 (en) Methods of treatment
GB202201825D0 (en) Methods of treatment
HK40099222A (en) T-type calcium channel modulators and methods of use thereof
EP4240352A4 (en) T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF
CA3300873A1 (en) Trpm3 modulators for treatment of pain
HK40072371A (en) Formulations of t-type calcium channel modulators and methods of use thereof
IL325944A (en) Treatment methods
HK40130651A (en) Treatment of opiod-induced pain
CA3274078A1 (en) Treatment of opiod-induced pain
GB202315695D0 (en) TReatment of cariomyopathy
GB202212506D0 (en) Treatment of covid-19
GB202206359D0 (en) Treatment of pain
HK40117335A (en) Methods of treatment using p-tau181 level
AU2023902382A0 (en) Methods of treatment